Plasma TGF-β1-related survival of postmenopausal metastatic breast cancer patients
| Autor: | M. Markicevic, Z. Nešković-Konstantinović, Nataša Todorović-Raković, Miroslav Demajo, D. Nikolić-Vukosavljević, B. Neskovic, Vesna Ivanovic |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.drug_class Breast Neoplasms Enzyme-Linked Immunosorbent Assay Transforming Growth Factor beta1 Radioligand Assay Transforming Growth Factor beta Surgical oncology Internal medicine medicine Humans Clinical significance Neoplasm Metastasis Receptor Survival analysis Hematology Estradiol biology business.industry General Medicine Transforming growth factor beta medicine.disease Survival Analysis Metastatic breast cancer Postmenopause Endocrinology Receptors Estrogen Estrogen biology.protein Female Receptors Progesterone business |
| Zdroj: | Clinical & Experimental Metastasis. 21:581-585 |
| ISSN: | 1573-7276 0262-0898 |
| DOI: | 10.1007/s10585-004-4978-1 |
| Popis: | A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta1 (TGF-beta1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta1 levels when compared to plasma TGF-beta1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors' status had no plasma TGF-beta1 values overlapping with patients having positive receptors' status. The TGF-beta1 cut-off value was defined as the highest plasma TGF-beta1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta1 cut-off value defined low-risk subgroup of 19 patients (or = 3.28 ng/ml) and high-risk subgroup of 10 patients (3.28 ng/ml) (P=0.047). Plasma TGF-beta1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta1 levels may be suggested. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink